| 1043 |
Management of QT Prolongation by Grade of Severity of ADR |
20/06/2022 |
|
| 1044 |
Management of Prolonged QTcF During Treatment with Shorter/Longer Oral MDR-TB Regimen |
20/06/2022 |
|
| 1045 |
State PMDT Committee: Terms of Reference [ToR] |
20/06/2022 |
|
| 1046 |
State Airborne Infection Control [AIC] Committee: Terms of Reference [ToR] |
20/06/2022 |
|
| 1047 |
Management of Hepato-toxicity During Treatment with H Mono/Poly DR-TB Regimen |
20/06/2022 |
|
| 1066 |
Mandatory Establishment of DR-TB Centres in All Medical Colleges |
20/06/2022 |
|
| 1067 |
Functions of District DR-TB Centre |
20/06/2022 |
|
| 1068 |
Requirements for Establishing District DR-TB Centres |
20/06/2022 |
|
| 1070 |
State Airborne Infection Control [AIC] Committee |
20/06/2022 |
|
| 1088 |
Methods for Pharmacovigilance Activity Reporting [aDSM] |
20/06/2022 |
|
| 1091 |
Severity Criteria for Reporting ADRs |
20/06/2022 |
|
| 1101 |
Rapid Molecular Drug-resistance Testing |
20/06/2022 |
|
| 1104 |
Use of M/XDR-TB Regimen in People Living with HIV [PLHIV] |
20/06/2022 |
|
| 1105 |
Pre-treatment Evaluation [PTE] in Longer Oral M/XDR-TB Regimen |
20/06/2022 |
|
| 1106 |
Use of Longer Oral M/XDR-TB Regimen in Severe Forms of Extrapulmonary TB and TB Meningitis |
20/06/2022 |
|
| 1108 |
Isoniazid [H] Mono/Poly DR-TB Regimen: Pre-treatment Evaluation |
20/06/2022 |
|
| 1110 |
Replacement Sequence in the H Mono/Poly DR-TB and Shorter Oral Bdq-containing MDR/RR-TB Regimens |
20/06/2022 |
|
| 1112 |
Use of Isoniazid [H] Mono/Poly DR-TB Regimen in Special Situations |
20/06/2022 |
|
| 1114 |
Interim Treatment Outcomes of DR-TB Cases |
20/06/2022 |
|
| 1115 |
Flow Chart of H Mono/Poly DR-TB Patients from Diagnosis to Treatment Outcome |
20/06/2022 |
|
| 1116 |
Flow Chart of MDR/RR-TB Patients on Shorter Oral Bedaquiline-containing Regimen from Diagnosis to Treatment Outcome |
20/06/2022 |
|
| 1117 |
Need for Palliative Care in DR-TB Patients |
20/06/2022 |
|
| 1290 |
TrueNAT Sample Processing: Other Body Fluids |
21/06/2022 |
|
| 1293 |
TrueNAT MTB Assay Results Interpretation: Detection of Mycobacterium tuberculosis and RIF Resistance |
21/06/2022 |
|
| 1298 |
External Quality Assurance of TrueNAT |
21/06/2022 |
|
| 1303 |
Visualization of CBNAAT Test Results |
21/06/2022 |
|
| 1331 |
Personal Protective Equipment [PPE] Use in TB Lab Settings |
21/06/2022 |
|
| 1350 |
Fluorescence Microscopy Using LED Microscope |
21/06/2022 |
|
| 857 |
Private Sector Engagement |
21/06/2022 |
|
| 851 |
Supply Chain Processes |
23/06/2022 |
|
